SAT0128 Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data

Abstract

BackgroundDisease-modifying therapies for RA have proven efficacy, but selective toxicities, such as malignancy, may increase with treatment duration. Periodic re-evaluation of incidence rates (IRs) allows assessment of any cumulative or...